These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 31493000)

  • 1. The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets.
    Nguyen JK; Austin E; Huang A; Mamalis A; Jagdeo J
    Arch Dermatol Res; 2020 Mar; 312(2):81-92. PubMed ID: 31493000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis.
    Gasparini G; Cozzani E; Parodi A
    Cytokine; 2020 Jan; 125():154799. PubMed ID: 31400638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-ranging, parallel group, split-face, single-blind phase II study of light emitting diode-red light (LED-RL) for skin scarring prevention: study protocol for a randomized controlled trial.
    Nguyen JK; Weedon J; Jakus J; Heilman E; Isseroff RR; Siegel DM; Jagdeo JR
    Trials; 2019 Jul; 20(1):432. PubMed ID: 31307501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of fibrotic changes by the synergistic effects of cytokines, dimensionality and matrix: Towards the development of an in vitro human dermal hypertrophic scar model.
    Chawla S; Ghosh S
    Acta Biomater; 2018 Mar; 69():131-145. PubMed ID: 29330036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-10 alleviates lipopolysaccharide-induced skin scarring via IL-10R/STAT3 axis regulating TLR4/NF-κB pathway in dermal fibroblasts.
    Shi J; Shi S; Xie W; Zhao M; Li Y; Zhang J; Li N; Bai X; Cai W; Hu X; Hu D; Han J; Guan H
    J Cell Mol Med; 2021 Feb; 25(3):1554-1567. PubMed ID: 33410606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of the Evidence for and against a Role for Mast Cells in Cutaneous Scarring and Fibrosis.
    Wilgus TA; Ud-Din S; Bayat A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33353063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay Between Keratinocytes and Fibroblasts: A Systematic Review Providing a New Angle for Understanding Skin Fibrotic Disorders.
    Russo B; Brembilla NC; Chizzolini C
    Front Immunol; 2020; 11():648. PubMed ID: 32477322
    [No Abstract]   [Full Text] [Related]  

  • 8. STAT6 suppression prevents bleomycin-induced dermal fibrosis.
    Huang J; Puente H; Wareing NE; Wu M; Mayes MD; Karmouty-Quintana H; Assassi S; Mills TW
    FASEB J; 2023 Feb; 37(2):e22761. PubMed ID: 36629780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the impact of fibroblast heterogeneity on skin fibrosis.
    Griffin MF; desJardins-Park HE; Mascharak S; Borrelli MR; Longaker MT
    Dis Model Mech; 2020 Jun; 13(6):. PubMed ID: 32541065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against TGF-β1-induced fibrosis effects of IL-10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring.
    Shi JH; Guan H; Shi S; Cai WX; Bai XZ; Hu XL; Fang XB; Liu JQ; Tao K; Zhu XX; Tang CW; Hu DH
    Arch Dermatol Res; 2013 May; 305(4):341-52. PubMed ID: 23321694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel methods for the investigation of human hypertrophic scarring and other dermal fibrosis.
    Honardoust D; Kwan P; Momtazi M; Ding J; Tredget EE
    Methods Mol Biol; 2013; 1037():203-31. PubMed ID: 24029937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The renin-angiotensin system in cutaneous hypertrophic scar and keloid formation.
    Hedayatyanfard K; Haddadi NS; Ziai SA; Karim H; Niazi F; Steckelings UM; Habibi B; Modarressi A; Dehpour AR
    Exp Dermatol; 2020 Sep; 29(9):902-909. PubMed ID: 32678966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Inflammasomes in Keloids and Hypertrophic Scars-Lessons Learned from Chronic Diabetic Wounds and Skin Fibrosis.
    Huang C; Ogawa R
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IL-4/IL-13 signaling axis promotes prostatic fibrosis.
    D'Arcy Q; Gharaee-Kermani M; Zhilin-Roth A; Macoska JA
    PLoS One; 2022; 17(10):e0275064. PubMed ID: 36201508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smad interacting protein 1 as a regulator of skin fibrosis in pathological scars.
    Zhang ZF; Zhang YG; Hu DH; Shi JH; Liu JQ; Zhao ZT; Wang HT; Bai XZ; Cai WX; Zhu HY; Tang CW
    Burns; 2011 Jun; 37(4):665-72. PubMed ID: 21236582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-33/ST2 Axis in Organ Fibrosis.
    Kotsiou OS; Gourgoulianis KI; Zarogiannis SG
    Front Immunol; 2018; 9():2432. PubMed ID: 30405626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-fibrotic actions of interleukin-10 against hypertrophic scarring by activation of PI3K/AKT and STAT3 signaling pathways in scar-forming fibroblasts.
    Shi J; Li J; Guan H; Cai W; Bai X; Fang X; Hu X; Wang Y; Wang H; Zheng Z; Su L; Hu D; Zhu X
    PLoS One; 2014; 9(5):e98228. PubMed ID: 24878845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward understanding scarless skin wound healing and pathological scarring.
    Karppinen SM; Heljasvaara R; Gullberg D; Tasanen K; Pihlajaniemi T
    F1000Res; 2019; 8():. PubMed ID: 31231509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
    Ogawa R; Akaishi S
    Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular Targets to Reduce Excessive Scarring in Response to Tissue Injury.
    Fertala J; Wang ML; Rivlin M; Beredjiklian PK; Abboud J; Arnold WV; Fertala A
    Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.